ChromaDex (ChromaDex) Float Percentage Of Total Shares Outstanding : 73.68% (As of May. 02, 2024)

View and export this data going back to 2008. Start your Free Trial

What is ChromaDex Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ChromaDex's float shares is 55.64 Mil. ChromaDex's total shares outstanding is 75.52 Mil. ChromaDex's float percentage of total shares outstanding is 73.68%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ChromaDex's Insider Ownership is 23.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ChromaDex's Institutional Ownership is 13.52%.

ChromaDex Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ChromaDex's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	55.64	/	75.52
	=	73.68%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChromaDex (ChromaDex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

OCD1:Germany

Address

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024

Website

https://www.chromadex.com

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.

Executives

Brianna Gerber	officer: SVP Finance / Interim CFO	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd	10 percent owner	C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr	director, 10 percent owner, officer: Chief Executive Officer	10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried	director	100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing	10 percent owner	79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly	10 percent owner	SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi	director	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen	director	C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick	director	3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary	director	ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington	officer: General Counsel	53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr	officer: Chief Financial Officer	MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245